Kubota Vision Inc. is a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. committed to translating innovation into a diverse portfolio of drugs and devices to preserve and restore vision for millions of people worldwide.
--(BUSINESS WIRE)-- Kubota Vision Inc. is a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596) committed to translating innovation into a diverse portfolio of drugs and devices to preserve and restore vision for millions of people worldwide. Kubota Vision’s development pipeline include drug candidates for the treatment of diabetic retinopathy, Stargardt disease, and optogenetics-based gene therapy for the treatment of retinitis pigmentosa. The company is also developing a handheld OCT device for the monitoring of neovascular retinal diseases, to be used directly by patients.
|
Company: |
Kubota Vision Inc. (dba of Acucela Inc.) |
|
|
Headquarters Address: |
818 Stewart Street, Suite 1110 |
|
|
Seattle, WA 98101 |
||
|
Main Telephone: |
+1.206.805.8300 |
|
|
Website: |
||
|
Type of Organization: |
Private |
|
|
Industry: |
Biotechnology, Medical Devices, Pharmaceutical |
|
|
Key Executives: |
CEO: Ryo Kubota |
|
|
Investor Relations |
||
|
Contact: |
Hiroki Maekawa |
|
|
Phone: |
+81.3.6550.8928 |
|
|
Email: |
||
|
Public Relations |
||
|
Contact: |
Yumiko Hamanaka |
|
|
Phone: |
+1.206.805.8300 |
|
|
Email: |
||
|
Business Development |
||
|
Contact: |
- - |
|
|
Email: |
View source version on businesswire.com: https://www.businesswire.com/news/home/20200401005734/en/
Source: Kubota Vision Inc.
View this news release online at:
http://www.businesswire.com/news/home/20200401005734/en
